Royalty Pharma plc (RPRX): what the price requires
At today's price, Royalty Pharma plc (RPRX) is priced for +3.4% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.
Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/RPRX
Headline
| Field | Value |
|---|---|
| Ticker | RPRX |
| Company | Royalty Pharma plc |
| Current price | $56.57/sh |
What The Price Requires (Inversion)
The assumption today's price embeds, recovered by inverting the valuation.
| Field | Value |
|---|---|
| Inversion basis | whole-company |
| Operating margin needed | 43.9% |
| Operating margin today | 72.7% |
| Margin compression implied | -28.8pp |
| Implied growth | 3.4% |
| Multiple paid | 23x operating income |
The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.
Solve inputs: computed at a 7% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~8.5pp (computed at the 7% minimum rate; the CAPM rate 6.9% sits below it).
Reconcile: at the x-ray's 9.3% required return this reads ~20.7%/yr; the models below use their own rates.
How unusual the bet is: within-range (limited comparison data)
| Reference | Value |
|---|---|
| vs own history | -0.30σ |
| implied end-window share | 0% |
Valuation X-Ray
Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).
How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.
| Family | Median price/FV | Models | Reads |
|---|---|---|---|
| Asset | 3.11x | 5 | expensive |
| Earnings | 2.43x | 4 | expensive |
| Relative | 1.89x | 3 | expensive |
| Growth | 0.73x | 3 | justifies |
Families that justify the price: Growth Families that call it expensive: Asset, Earnings, Relative
The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.3%); the inversion above states its own rate.
Per-Model Detail (n=15)
| Model | Family | FV | Price/FV | Applicable | Methodology |
|---|---|---|---|---|---|
| DCF Perpetual Growth | Growth | $152.70 | 0.37x | yes | FCF base $2.8B, growth 8% (input: historical growth), terminal g 4.0%, WACC 7.3%, 6yr projection |
| DCF Exit Multiple | Growth | $77.47 | 0.73x | yes | Exit EV/EBITDA: 23.3x / 25.3x / 27.3x (bear / base = today's held flat / bull), 6yr |
| Relative Valuation | Relative | $41.55 | 1.36x | yes | P/E 28.22x (blended: static sector reference 24x + trailing (TTM) 38x), scenarios: 23.5x / 28.2x / 33.0x (bear / base = reference held flat / bull), EV/EBITDA 18.8x |
| Simple DDM | Growth | — | — | no | — |
| Two-Stage DDM | Growth | — | — | no | — |
| Simple Excess Return | Asset | $16.06 | 3.52x | yes | BV/sh $12.37, ROE (TTM) 12.0%, ke 9.3% |
| Two-Stage Excess Return | Asset | $18.19 | 3.11x | yes | 5yr excess ROE then converge to ke=9.3% |
| Discounted Future Market Cap | Growth | $29.09 | 1.94x | yes | Rev $2.4B, growth 8% (input: historical growth; tapered), Terminal P/S: 6.7x / 8.0x / 9.3x (bear / base = today's held flat / bull, cap 8x) |
| Growth-Adjusted P/E | Relative | — | — | no | — |
| Margin Trajectory | Growth | — | — | no | — |
| Earnings Power Value | Earnings | $9.44 | 5.99x | yes | Normalized EBIT (5y avg op income, one-time charges added back) $1.30B × (1−21%) / WACC 7.3% → EPV (no growth) |
| Residual Income | Asset | $18.62 | 3.04x | yes | BV $12.37 + 5yr PV of (ROE (TTM) 12.0% − Kₑ 9.3%) × BV; BV grows 7.8%/yr |
| Graham Number | Asset | $23.00 | 2.46x | yes | √(22.5 × EPS $1.90 × BVPS $12.37) — Graham's conservative floor |
| EV/EBITDA Relative | Relative | $29.96 | 1.89x | yes | EBITDA $1.59B × sector EV/EBITDA 16.0x |
| FCF Yield | Earnings | $35.00 | 1.62x | yes | FCF $2612.0M / Kₑ 9.3% — zero-growth perpetuity |
| SBC-Adj FCF Yield | Earnings | $26.99 | 2.10x | yes | SBC-adj FCF $2.20B (FCF $2.61B − SBC $0.41B) capitalized at Kₑ |
| Ben Graham Formula | Earnings | $1.59 | 35.58x | yes | EPS $1.90 × (8.5 + 2×-5.0%) × (4.4 / 5.3%) (excluded from median) |
| ROIC-Justified P/B | Asset | $4.81 | 11.76x | yes | BV $12.37 × (ROIC 2.8% / WACC 7.3%) |
| P/Sales Sector | Relative | $17.53 | 3.23x | yes | Revenue $2.44B × sector P/S 4.0x |
| PEG Fair Value | Relative | — | — | no | — |
| Earnings Yield | Earnings | $20.54 | 2.75x | yes | EPS $1.90 / required return 9.3% (Rf 4.3% + ERP 5.0%) |
| Funds From Operations Multiple | Relative | — | — | no | — |
| Clinical Phase NPV | Growth | — | — | no | — |
| Merton | Asset | — | — | no | — |
| V5 Mechanical | — | — | — | no | — |
Solvency
| Field | Value |
|---|---|
| Net debt | $8.3b |
| Net debt / NOPAT (after-tax) | 6.09x |
| Net debt / operating income (pre-tax) | 4.81x |
| Interest coverage | 5.6x |
| Share count CAGR (buyback) | -2.1% |
| Burning cash | no |
Bullet Takeaways
- Royalty Pharma is not a drugmaker; it buys royalty streams on approved and late-stage drugs, which is why it runs a 65% operating margin on about $2.4B of revenue without owning a single lab bench.
- The whole business is a treadmill: existing royalties decline as patents expire, so new investment must continually replace them, and the company deployed $528 million in Q1 2026 alone.
- The watch item is portfolio receipts: management raised full-year 2026 guidance to $3.325 billion to $3.45 billion after a quarter of 10% receipts growth.
Bull Case
Valuing Royalty Pharma starts with understanding that it sells money, not medicine. It funds drug developers in exchange for a cut of future sales, and the filing frames the opportunity precisely: an industry where "the potential for multiple royalties to be created from each new drug that reaches the" market keeps the deal pipeline full. That structure produces an extraordinary cost line, a 65% operating margin, because there are no factories, no sales reps, and no failed-trial write-offs of its own. It collects checks on drugs other companies discovered, manufactured, and marketed.
The model diversifies away the single biggest risk in biotech, which is that any one drug fails. Royalty Pharma holds a portfolio of streams across many therapies, so the bet is on aggregate prescription volume rather than on a binary clinical readout. That is the bull's structural advantage: a cash-flow machine with the upside exposure of pharma and a fraction of its idiosyncratic risk. Q1 2026 showed the engine running, with portfolio receipts up 10% to $925 million, royalty receipts up 13%, and net cash from operations of $718 million.
The growth comes from redeploying that cash into new royalties, and the recent cadence is heavy. The company announced $1.25 billion of new transactions in the quarter across three therapies, including research-and-development co-funding deals with J&J and Teva worth about $1 billion in announced value, while raising the dividend 7%. Management lifted full-year portfolio receipts guidance to $3.325 billion to $3.45 billion. The bull case is that the team keeps finding royalties that earn more than the cost of the capital used to buy them, compounding a diversified stream of pharma cash flows the static valuation frames struggle to price.
Bear Case
Every royalty Royalty Pharma owns is decaying toward the day its drug loses patent protection, and that erosion is the central bear thesis. The filing is blunt that the business model is a treadmill: ongoing investment in new royalties is fundamental because it must supplement existing growth while "offsetting declines" in the portfolio. The company's own 2026 guidance already names the specific erosions in flight: the loss of exclusivity for Promacta, the launch of biosimilar Tysabri in the United States, and the potential impact of U.S. drug-pricing legislation. The moat is not a fortress that holds; it is a bucket that leaks, and the only way to keep the level up is to keep pouring in new water.
That makes the business uniquely dependent on capital deployment that earns its keep. If the team overpays for new royalties, or if the deal market gets crowded and returns compress, growth stalls even as the existing portfolio runs off. The company deployed $528 million in Q1 2026 and announced $1.25 billion of new transactions, so the run rate of capital it must commit just to stand still is large. Each deal is an underwriting bet on a drug's future sales curve, and a few that disappoint would show up as receipts that grow slower than the cost of the capital raised to fund them.
The balance sheet adds a second pressure to that dynamic. Net debt is about $8.35 billion, roughly 5.3 times operating income, with interest covered about 4.7 times. That leverage funds the new royalties, so the model is borrowing to replace a depreciating asset base, and a higher-for-longer rate environment raises the cost of the very capital the growth depends on. The price reflects a within-range bet on modest forward growth, but the asset-value and earnings-power methods both read it as expensive, several landing well below it, because they value the royalties on the books today and credit nothing to the deals still to be sourced. The bear does not need the price to be absurd; it needs the deployment engine to slip, and the patent cliffs do not wait.
Valuation
At about 22 times operating income, the price is making a measured bet for a business with this margin profile. Inverted, it implies company-wide operating growth of roughly 2% a year over a five-year window, against a current operating margin of 65%, the signature of a royalty collector rather than a drug developer. The near-term pace the price requires is within what Royalty Pharma has recently delivered, so the read is broadly consistent with plausible growth rather than a stretch on the rate. The stretch, if any, is in how durably the portfolio keeps replacing its own runoff.
The methods split along a familiar line for a cash-rich, leveraged compounder. The asset-value and earnings-power families read the price as expensive, several landing well below it, because they value the existing royalty book and assign nothing to future deals. Only the forward-growth methods reach the price, and they do so by crediting continued reinvestment at attractive returns. The peer-multiple lens is awkward here, because the screen's healthcare peers are operating companies rather than royalty aggregators, so the cleaner read is the structural one: the price is paying for the deployment engine to keep sourcing royalties that out-earn their cost of capital.
Solvency is where the model's cost lives. Net debt of about $8.35 billion is roughly 5.3 times operating income with interest covered about 4.7 times, leverage that funds the royalty purchases rather than signaling distress, but leverage that makes the cost of capital a live variable in the growth story. The share count has fallen about 2.1% a year on buybacks, and the dividend was raised 7%, so capital return is real even as the company keeps spending to grow. The decisive question is not the multiple; it is whether new royalties keep earning more than the capital used to buy them faster than the existing portfolio runs down.
Catalysts
Q1 2026 started the year with double-digit cash growth. Portfolio receipts rose 10% to $925 million, royalty receipts grew 13%, and net cash from operations was $718 million. On that strength, management raised full-year 2026 portfolio receipts guidance to $3.325 billion to $3.45 billion, from a prior $3.275 billion to $3.425 billion, and guided Q2 portfolio receipts to $740 million to $760 million. The guidance assumes royalty receipts growth of roughly 4% to 8%, after absorbing the Promacta loss of exclusivity, biosimilar Tysabri in the United States, and potential drug-pricing-policy effects.
The deal flow was the other headline, and for this business deals are the growth. The company announced $1.25 billion of new transactions across three therapies, including R&D co-funding arrangements with J&J and Teva totaling about $1 billion in announced value, and deployed $528 million in the quarter, mainly on Ziihera, Avlayah, and a Trelegy milestone. It also repurchased 1 million shares for $50 million and raised the dividend 7%, a mix of growth investment and capital return.
What to watch is the pace and pricing of new royalty acquisitions against the known patent erosions in the portfolio. The next receipts print tests whether the new deals are offsetting the Promacta and Tysabri declines, and any large transaction announcement resets the forward growth trajectory. The interplay of deployment and runoff is the whole story for a royalty aggregator.
Peer Cohorts (Per Segment, With Filing Citations)
Core business (reported)
- LGND (LIGAND PHARMACEUTICALS INCORPORATED)
- (no filing in the citation store)
Methodology Note
- Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
- Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
- Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
- Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.
Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.
Sources
Royalty Pharma Q1 2026 earnings release, May 2026